for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

60.75USD

Change

-0.52(-0.85%)

Volume

3,048,462

Today's Range

59.97

 - 

61.35

52 Week Range

45.77

 - 

67.15

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb With Phase 1B Combination Study Of Com701 With Opdivo®

Feb 22 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN EXPANDS CLINICAL COLLABORATION AGREEMENT WITH BRISTOL MYERS SQUIBB WITH PHASE 1B COMBINATION STUDY OF COM701 WITH OPDIVO®.COMPUGEN LTD - BRISTOL MYERS SQUIBB WILL SUPPLY OPDIVO FOR COMPUGEN'S PHASE 1B COHORT EXPANSION STUDY DESIGNED TO ASSESS COM701.COMPUGEN LTD - CO'S ANTI-PVRIG ANTIBODY, IN COMBINATION WITH OPDIVO IN SELECTED CANCER INDICATIONS. STUDY INITIATION IS EXPECTED IN Q2 OF 2021.

Bristol Myers Squibb Canada Says Health Canada Approved Reblozyl

Feb 16 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::HEALTH CANADA APPROVES REBLOZYL (LUSPATERCEPT), NEW CLASS OF TREATMENT FOR ADULT PATIENTS LIVING WITH MYELODYSPLASTIC SYNDROMES.

Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb For The Discovery And Development Of Next Generation Engineered Toxin Bodies For The Treatment Of Cancer

Feb 11 (Reuters) - Molecular Templates Inc <MTEM.O>::MOLECULAR TEMPLATES ESTABLISHES MULTI-TARGET COLLABORATION WITH BRISTOL MYERS SQUIBB FOR THE DISCOVERY AND DEVELOPMENT OF NEXT GENERATION ENGINEERED TOXIN BODIES FOR THE TREATMENT OF CANCER.MOLECULAR TEMPLATES - BRISTOL MYERS TO HAVE OPTION TO OBTAIN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP, COMMERCIALIZE ETBS DIRECTED TO EACH SELECTED TARGET.MOLECULAR TEMPLATES INC - BRISTOL MYERS SQUIBB WILL MAKE AN UP-FRONT PAYMENT OF $70 MILLION TO MTEM.MOLECULAR TEMPLATES - IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO ABOUT $1.3 BILLION AS WELL AS TIERED ROYALTY PAYMENTS ON FUTURE SALES.

Opdivo® (Nivolumab) In Combination With Cabometyx® (Cabozantinib) Shows Sustained Survival And Response Rate Benefits As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma In T

Feb 8 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::OPDIVO® (NIVOLUMAB) IN COMBINATION WITH CABOMETYX® (CABOZANTINIB) SHOWS SUSTAINED SURVIVAL AND RESPONSE RATE BENEFITS AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE PHASE 3 CHECKMATE -9ER TRIAL.BRISTOL-MYERS - PATIENTS TREATED WITH OPDIVO IN COMBINATION WITH CABOMETYX REPORT SIGNIFICANTLY IMPROVED HEALTH-RELATED QUALITY OF LIFE.

Adjuvant Treatment With Opdivo (Nivolumab) Shows Statistically Significant And Clinically Meaningful Improvement In Disease-Free Survival In Patients With Muscle-Invasive Urothelial Carcinoma In

Feb 8 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::ADJUVANT TREATMENT WITH OPDIVO (NIVOLUMAB) DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL IN PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA IN PHASE 3 CHECKMATE -274 TRIAL.BRISTOL-MYERS SQUIBB - PATIENTS WHO RECEIVED OPDIVO AFTER SURGERY LIVED NEARLY TWICE AS LONG WITHOUT DISEASE RECURRENCE VERSUS THOSE WHO RECEIVED PLACEBO.BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN PATIENTS WITH SOLID TUMORS.BRISTOL-MYERS SQUIBB - WITH POSITIVE RESULTS FROM CHECKMATE -274, OPDIVO SHOWN BENEFIT IN PHASE 3 TRIALS ACROSS 4 DIFFERENT TYPES OF EARLY RESECTABLE CANCER.BRISTOL-MYERS SQUIBB - TREATMENT-RELATED ADVERSE EVENTS OCCURRED IN 77.5% OF PATIENTS WHO RECEIVED OPDIVO VERSUS. 55.5% OF PATIENTS WHO RECEIVED PLACEBO.

Bristol-Myers Squibb Qtrly Rev $11.07 Bln vs $7.95 Bln

Feb 4 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::QTRLY REVENUE $11.07 BILLION VERSUS $7.95 BILLION.QTRLY GAAP LOSS PER SHARE $4.45; QTRLY NON-GAAP EARNINGS PER SHARE $1.46.Q4 EARNINGS PER SHARE VIEW $1.42, REVENUE VIEW $10.73 BILLION -- REFINITIV IBES DATA.IPR&D CHARGE OF $11.4 BILLION INCLUDED IN QUARTER DUE TO MYOKARDIA TRANSACTION BEING ACCOUNTED FOR AS AN ASSET ACQUISITION.AMORTIZATION OF ACQUIRED INTANGIBLE ASSETS INCREASED TO $2.5 BILLION IN QUARTER REFLECTING FULL QUARTER AMORTIZATION FROM CELGENE DEAL.QTRLY WORLDWIDE OPDIVO REVENUE $1.79 BILLION, UP 2%.QTRLY WORLDWIDE ELIQUIS REVENUE $2.27 BILLION, UP 12%.QTRLY WORLDWIDE REVLIMID REVENUE $3.28 BILLION, UP 18% ON PRO FORMA BASIS.ANNOUNCES DEBT TENDER OFFER FOR AGGREGATE PURCHASE PRICE OF UP TO $4.0 BLN.SEES 2021 GAAP EPS IN RANGE OF $3.12 - $3.32.INCREASING 2021 NON-GAAP EPS GUIDANCE RANGE FROM $7.15 - $7.45 TO $7.35 - $7.55.2021 GUIDANCE ASSUMES WORLDWIDE REVENUES INCREASING IN HIGH-SINGLE DIGITS.FY2021 EARNINGS PER SHARE VIEW $7.45, REVENUE VIEW $46.00 BILLION -- REFINITIV IBES DATA.AFFIRMING 2020-2025 LONG-TERM FINANCIAL TARGETS COMMUNICATED IN JANUARY 2021.DURING 2021, COMPANY PLANS TO REPURCHASE $3.0 BILLION - $4.0 BILLION OF ITS SHARES.

Bristol Myers Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study

Feb 2 (Reuters) - Bristol Myers: :BRISTOL MYERS ANNOUNCES POSITIVE TOPLINE RESULTS FROM SECOND PIVOTAL PHASE 3 PSORIASIS STUDY SHOWING SUPERIORITY OF DEUCRAVACITINIB VERSUS PLACEBO AND OTEZLA.OVERALL SAFETY PROFILE REMAINS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS.OVERALL SAFETY PROFILE CONSISTENT WITH MECHANISM OF ACTION OF DEUCRAVACITINIB, AN ORAL SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR.SUPERIORITY OF DEUCRAVACITINIB WAS DEMONSTRATED ON BOTH CO-PRIMARY ENDPOINTS, MULTIPLE KEY SECONDARY ENDPOINTS IN POETYK PSO-2 TRIAL.

Bristol-Myers Squibb Application For Zeposia For The Treatment Of Ulcerative Colitis Accepted For Filing With Priority Review By U.S. Food And Drug Administration

Feb 1 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB APPLICATION FOR ZEPOSIA® (OZANIMOD) FOR THE TREATMENT OF ULCERATIVE COLITIS ACCEPTED FOR FILING WITH PRIORITY REVIEW BY U.S. FOOD AND DRUG ADMINISTRATION.BRISTOL-MYERS SQUIBB CO - U.S. FOOD AND DRUG ADMINISTRATION ASSIGNED AN ACTION DATE OF MAY 30, 2021.

U.S. Food And Drug Administration Approves Opdivo In Combination With Cabometyx As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma

Jan 22 (Reuters) - Bristol-Myers Squibb Co <BMY.N>:U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) IN COMBINATION WITH CABOMETYX® (CABOZANTINIB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.BRISTOL-MYERS SQUIBB CO - IN CHECKMATE -9ER, OPDIVO IN COMBINATION WITH CABOMETYX DOUBLED MEDIAN PROGRESSION-FREE SURVIVAL AND OBJECTIVE RESPONSE RATE.

U.S. Food And Drug Administration Accepts For Priority Review Application For Opdivo® (Nivolumab) Combined With Chemotherapy

Jan 20 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR PRIORITY REVIEW APPLICATION FOR OPDIVO® (NIVOLUMAB) COMBINED WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT IN METASTATIC GASTRIC CANCER, GASTROESOPHAGEAL JUNCTION CANCER AND ESOPHAGEAL ADENOCARCINOMA.BRISTOL-MYERS SQUIBB CO - U.S. FOOD AND DRUG ADMINISTRATION ASSIGNED A TARGET ACTION DATE OF MAY 25, 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up